COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile? (Q34475705)

2 August 2017

1 reference

title

COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile? (English)

1 reference

2 August 2017

Simon LS

1

1 reference

2 August 2017

1 December 2001

1 reference

Gastroenterology Clinics of North America

2 August 2017

1 reference

2 August 2017

30

1 reference

2 August 2017

4

1 reference

2 August 2017

1011-25, viii

1 reference

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Nonsteroidal antiinflammatory drugs--differences and similarities

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Basic biology and clinical application of specific cyclooxygenase-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Nonsteroidal Antiinflammatory Drugs and Gastrointestinal Hospitalizations in Saskatchewan: A Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Inducible cyclooxygenase may have anti-inflammatory properties

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Aspirin and the Risk of Colorectal Cancer in Women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Nonsteroidal anti-inflammatory drug gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Are selective COX-2 inhibitors nephrotoxic?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

NSAIDs, gastrointestinal injury, and cytoprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Renal complications of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Distribution of COX-1 and COX-2 in normal and inflamed tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

The relationship between cyclooxygenase-2 expression and colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Pharmacological analysis of cyclooxygenase-1 in inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Effects of celecoxib and naproxen on renal function in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970226-0

7 January 2021

10.1016/S0889-8553(05)70226-0

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11764530